Exchange & Returns Information
Review Details
(0)
| Generic For | XTANDI |
|---|---|
| Active Ingredient | ENZALUTAMIDE |
| Strength | 40MG |
| Manufacturer | DR REDDYS LABORATORIES |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 112 TABLETS | $ 2.52 | $ 282.00 |
$ 239.70
Apply ZARVY26 (-15%)
You save $ 42.30
|
||
| 2 BOXES - 224 TABLETS | $ 2.46 |
2% $ 564.00
$ 552.00
|
$ 469.20
Apply ZARVY26 (-15%)
You save $ 82.80
|
||
| ★ Best Value 3 BOXES - 336 TABLETS | $ 2.39 |
5% $ 846.00
$ 802.00
|
$ 681.70
Apply ZARVY26 (-15%)
You save $ 120.30
|
Reference information will be available soon.
Azel 40 is an oral oncology drug containing enzalutamide, a next-generation androgen receptor (AR) signaling inhibitor used for advanced prostate cancer. Unlike older antiandrogens, it blocks multiple steps of the AR signaling pathway, including nuclear translocation, DNA binding, and coactivator recruitment. It offers substantial clinical benefit across various stages of prostate cancer—both before and after chemotherapy—and is especially favored due to its steroid-free monotherapy profile.
AntiCancer Drugs > Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Azel 40 is indicated for men with mCRPC who have progressed despite prior ADT. It can be used before or after chemotherapy. Enzalutamide significantly improves PSA response, radiographic progression-free survival, and overall survival without the need for corticosteroids.
> Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC)
For patients with rising PSA but no evidence of metastasis on imaging, Azel 40 delays time to metastasis. This treatment option provides early disease control and improves metastasis-free survival.
> Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Enzalutamide is also approved for use in combination with ADT as a first-line treatment in high-risk mCSPC. It can be used with or without chemotherapy, making it a versatile therapeutic choice in early metastatic prostate cancer.
> Biochemical Recurrence (Off-label)
In cases of biochemical recurrence—where PSA levels rise despite no radiographic metastasis—enzalutamide is under investigation as an off-label option to delay overt disease progression.
Azel 40 selectively inhibits AR signaling at multiple stages. It is effective across CRPC and CSPC, in both metastatic and non-metastatic settings. Unlike abiraterone, it eliminates the need for corticosteroids. Clinical trials have demonstrated improvements in survival outcomes and disease control.
The usual adult dose for prostate cancer is 160 mg orally once daily (four Azel 40 tablets). It may be taken with or without food, but tablets must not be chewed, crushed, or opened. Therapy should be used in combination with a GnRH analog or after bilateral orchiectomy. Treatment continues until disease progression or intolerable toxicity. Patients should be monitored for blood pressure, fall risk, fatigue, and potential seizure activity during long-term use. Dose adjustments may be required in cases of severe adverse reactions.
Store in a cool, dry place below 25°C. Avoid exposure to moisture and direct sunlight. Keep the medication in its original packaging until use. Ensure it is stored out of reach of children.
Common side effects include fatigue, hot flashes, hypertension, and musculoskeletal pain. Rare but serious effects include seizures (especially in predisposed patients) and cognitive changes. Long-term use may lead to falls or weight loss in elderly populations. Routine assessment of neurological and cardiovascular health is strongly recommended.
No reviews yet. Be the first to review this product!
No combo deals available at the moment.
